Abstract
Background and Aims: Dietary gangliosides are present in human milk and consumed in low amounts from organ meats. Clinical and animal studies indicate that dietary gangliosides attenuate signaling processes that are a hallmark of inflammatory bowel disease (IBD). Gangliosides decrease pro-inflammatory markers, improve intestinal permeability, and reduce symptoms characteristic in patients with IBD. The objective of this study was to examine mechanisms by which dietary gangliosides exert beneficial effects on intestinal health.
Methods: Studies were conducted in vitro using CaCo-2 intestinal epithelial cells. Gangliosides were extracted from milk powder and incubated with differentiated CaCo-2 cells after exposure to pro-inflammatory stimuli. Gut barrier integrity was assessed by electron microscopy, epithelial barrier function was examined by measuring transepithelial electric resistance, and content of HBD-2, IL-23, NF-κB, and sPLA2 was assessed by ELISA.
Results: Ganglioside attenuated the decrease in integrity of tight junctions induced by pro-inflammatory stimuli and improved epithelial barrier function (P < 0.05). Ganglioside decreased the basolateral secretion of sPLA2 (P ≤ 0.05), lowered HBD-2 and IL-23 levels (P ≤ 0.05), and inhibited NF-κB activation (P ≤ 0.05).
Conclusions: In summary, the present study indicates that ganglioside GD3 improves intestinal integrity by altering sPLA2 trafficking, and the production of pro-inflammatory mediators is mitigated by decreasing assembly of the NF-κB complex. Dietary gangliosides may have promising potential beneficial effects in IBD as decreased inflammatory signaling, improved intestinal integrity, and maintenance of epithelial barrier function have been demonstrated in vitro.
Introduction
Inflammatory bowel disease (IBD) is a chronic, relapsing disorder resulting from persistent inflammation affecting the mucosa of the gastrointestinal tract (1). Management of Crohn disease (CD) and ulcerative colitis (UC) is challenging and may consist of drug treatments including glucocorticosteroids, immunosuppressants, and/or biologics. Some individuals with IBD do not respond to drug treatment, while others experience adverse effects associated with treatment (2). Failure to maintain remission is common, thus new treatment initiatives are urgently needed.
Individuals consuming diet abundant in anti-inflammatory bioactives have a reduced risk for CD (3). Gangliosides are a class of polar lipids abundantly expressed in the nervous system and found ubiquitously in tissues and body fluids, including human milk (4). Ingestion of dietary ganglioside was shown to be safe at 43 mg/day for 8 weeks in adults (5). The bioavailability of ganglioside has been demonstrated as plasma concentration of ganglioside GD3 increased 40% within 2 weeks of supplementation with ganglioside in healthy adults and in adults with IBD (5). Dietary gangliosides consumed from a complex milk-lipid fraction reduced intestinal permeability by 19% in healthy adults, and also improved emotional health and systemic symptoms in a pilot study of five participants with IBD without a placebo control after 8 weeks of consumption (5). Dietary ganglioside is safe for consumption and has demonstrated clinical benefit in patients with IBD.
Reduction of ganglioside content is a hallmark of intestinal inflammation (2). The content of ganglioside catabolic enzymes beta-hexosaminidase and sialidase are elevated in the intestinal mucosa of patients with IBD relative to a control group (6), suggesting a depletion of ganglioside GD3 species in CD and UC. Exposure of infant bowel to ganglioside ex vivo reduced bowel necrosis and endothelin-1 production in response to lipopolysaccharide (LPS) (7). Dietary gangliosides increase cellular ganglioside content and decrease cholesterol content of microdomains in a rodent model (8). Reduced content of cholesterol in enterocyte membranes inhibits cellular entry of pathogens (9) and decreases the generation of pro-inflammatory signals (8). The mechanisms underlying the mitigation of pro-inflammatory signaling by dietary gangliosides remains largely unknown.
Intestinal epithelial cells are a key component to the physiologic barrier between the myriad of toxins, microbes, and antigens present in the gut lumen and the underlying mucosal immune system (10). Defects in the intestinal barrier and impaired immune function are characteristic of IBD. Disruption of intestinal barrier function results in increased permeability of the host gut to luminal antigens and bacteria, leading to the immune response and inflammation (11). Para-cellular permeability is regulated by a complex of macromolecules commonly described as adherens or tight junctions. IL-1β induces the expression of miR-200c-3p which causes a downregulation of the tight junction protein occludin (12). Dietary ganglioside has been reported to inhibit degradation of occludin in a preclinical model of IBD (13). Secretory phospholipase A2 (sPLA2) is a ubiquitous group of enzymes implicated in turnover of membrane phospholipids and lipid digestion. Activated sPLA2 catalyzes release of fatty acids from the sn-2 position of phospholipid in membranes, which is the first step in production of eicosanoids and other inflammatory mediators (14) that result in degradation of tight junction proteins.
Human beta-defensin (HBD)-2 coordinates innate and acquired immune responses (15) through nuclear factor-κB (NF-κB) (16). NF-κB is a primary regulator of inflammatory responses and plays a critical role in a variety of physiological and pathologic processes. Activation of NF-κB stimulates production of interleukin-23 (IL-23) (17). After binding to the IL-23 receptor, the production tumor necrosis factor alpha (TNF-α) is stimulated from T-cells thus contributing to the pathogenesis of IBD (18). It is crucial that efficacious therapies reduce TNF-α to induce clinical, endoscopic, and histopathological healing (19).
The focus of this study was to determine the potential mechanism by which ganglioside protects barrier integrity and function in a model of intestinal cell inflammation. It is hypothesized that ganglioside GD3 sustains barrier activity by decreasing secretion of sPLA2, inhibiting NF-κB activation, and mediating pro-inflammatory signaling.
Methods
All authors had access to the study data and had reviewed and approved the final manuscript.
Cell Culture
The human colon adenocarcinoma epithelial cell line CaCo-2 (American Type Culture Collection® HTB-37TM) was grown in complete medium (EMEM, Invitrogen), 10% (v/v) FBS, 1% (v/v) antibiotic/antimycotic, 26 mM sodium bicarbonate, 10 mM HEPES, 1 mM pyruvic acid, (37°C, 5% CO2). Cells were passaged at 90% confluence using 0.25% trypsin-2.65 mM EDTA and subcultured at a density of 1.6 × 104 cells/cm2. All studies were performed on confluent cells of the CaCo-2 subclone between passages 20 and 40.
Preparation of Ganglioside
Gangliosides were extracted from Zeta lipid-2 milk powder (Fonterra, Cambridge, New Zealand). Powder was added (1:60 w/v) to chloroform/methanol (C/M) (2:1 v/v), vortexed, and shaken (>2 h). Tubes were inversed several times after adding 0.025% (w/v) CaCl2/H2O. After centrifugation, the upper layer was withdrawn and applied to a Sep-Pak Classic C18 cartridge (Waters). Cartridges were rinsed with H2O before eluting ganglioside with methanol, followed by C/M (2:1 v/v). For quantification, aliquots (duplicate) were dried under N2 gas before H2O addition and vortex. Resorcinol-HCl was added to tubes before vortex and heating (160°C; 8 min). After cooling to room temperature, butylacetate/butanol (85:15 v/v) was added to tubes and vortexed. The upper layer was withdrawn and optical density was determined on a spectrophotometer (8452A, Hewlett Packard) at 580 nm. Total ganglioside was quantified as ganglioside-bound N-acetyl neuraminic acid with an N-acetyl neuraminic acid standard (SigmaAldrich). Gangliosides were dissolved in media (10 μg/ml) and all media were sonicated (130 W, 30 sec) prior to filter sterilization through a 0.2 μm syringe filter to facilitate dissolution of potential micelle formation.
Stimulation of Cells
CaCo-2 cells were cultured at a density of 2.5 × 107 cells/ml on 0.4 μm pore inserts in transwell plates (Corning Costar). The apical (upper) and basolateral (lower) compartments contained 0.5 and 2 ml of medium, respectively. After becoming confluent, cultures were then grown for 3 weeks to facilitate differentiation and expression of villi, microvilli, and small intestinal enterocyte function (20). Cells were divided into groups with the following experimental conditions for 48 h: grown in complete medium (control), incubated with ganglioside (10 μg/ml), exposure to LPS (100 μg/ml), or exposure to DSS (2.5%; Sigma Aldrich). Ganglioside was added to the culture medium 19 days after cultures became confluent. The cells were incubated for 24 h with LPS or for 48 h with DSS from the apical side 21 days after cultures became confluent. Culture media were collected and analyzed for HBD-2, IL-23, and sPLA2; and cells were harvested for analysis of NF-κB.
Electron Microscopy
CaCo-2 cell monolayers were incubated in 2.5% (w/v) of glutaraldehyde/cacodylate buffer (pH 7.2) for 1.5 h and subsequently washed in this same buffer three times for 15 min before being fixed in 1% (v/v) osmium tetroxide buffer for 1.5 h at room temperature. Cells were then rinsed in distilled water; dehydrated in a series of 50, 70, and 90% absolute ethanol for 10 min. Samples were then embedded in Spurr's resin mixture (Spurr's resin/ethanol 50:50). Following polymerization at 70°C for 12 h, ultrathin sections were cut, stained with uranyl acetate and lead citrate, and viewed with a Hitachi H7000 Transmission Electron Microscope (Tokyo, Japan), or with a Hitachi Scanning Electron Microscope S2500 (Tokyo, Japan) using a method previously described (21) to examine the integrity of monolayers.
TEER Assessment
Transepithelial electrical resistance (TEER) was assessed as an index of confluence, integrity and barrier function of cell monolayers (22). TEER of CaCo-2 monolayers grown on collagen-coated filter inserts was measured using a Volt Meter (World Precision Instruments, Hamden, CT). The TEER value measured in the absence of cells was used as background. The TEER of monolayers without added DSS or ganglioside represented the controls for each experiment. The TEER was measured in cell culture medium within one min of removing from incubator (37°C) before addition of pro-inflammatory stimulus (time zero) and then at time intervals and expressed as the ratio of the TEER at time t to the initial value (at time zero) for each series. Time course measurements were obtained independently from unique transwells.
Measurement of Pro-inflammatory Markers and Immune Mediators
NF-κB activation was assessed using a TransAM NF-κB transcription factor family assay kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions. Human IL-23, HBD-2, and sPLA2 were assayed from cell supernatants using titerzyme ELISA Kits, according to the manufacturer's instructions (R&D Systems, Minneapolis, MN; Phoenix Pharmaceuticals Inc.; Cayman Chemicals, MI). A microplate reader (Eppendorf BioPhotometer) was used to determine optical density at 450 nm and corrected for background at 540 nm.
Statistical Analysis
The study data may be made available to other researchers upon request. All experiments were independently replicated at least three times at different cell passages. Data are presented as mean ± SD. Statistical testing was conducted using an ANOVA or Duncan's multiple range test. There was no interaction between LPS and ganglioside when analyzed by a two-way ANOVA. An α value below 0.05 was considered statistically significant.
Results
Ganglioside Protected Intestinal Tight Junction and Adhesion Junction Proteins
Visualization of CaCo-2 cell monolayer by electron microscopy revealed intact tight junctions, adherens junctions, and desmosomes in control cells (Figure 1A). DSS induced the opening and disruption of tight junctions and desmosomes (Figure 1B) which was attenuated by ganglioside (Figure 1C). Pre-incubation with ganglioside prevented the decrease in TEER induced by LPS and DSS (Figure 2).
Figure 1
Figure 2
Ganglioside Regulates Phospholipase Activity
The concentration of sPLA2 was elevated after incubation with LPS and ganglioside (Figures 3A,B). Pre-incubation with ganglioside mitigated the DSS-induced trafficking of sPLA2 to the basolateral membrane (Figures 3C,D).
Figure 3
Ganglioside Decreased Pro-inflammatory Cytokine Levels
LPS stimulation increased HBD-2 and IL-23 in the apical media from differentiated CaCo-2 cell monolayers (Figure 4). Incubation with ganglioside alone did not affect HBD-2 concentration compared to control. Pre-incubation with ganglioside mitigated the increases in HBD-2 and IL-23 content induced by pro-inflammatory stimulus (Figure 4). Incubation with pro-inflammatory stimuli significantly increased NF-κB activation in CaCo-2 cells (Figure 5). Pre-incubation with ganglioside reduced LPS-mediated activation of NF-κB P65 and P52 subunits (Figures 5A,B), but not P60 subunit (Figure 5C).
Figure 4
Figure 5
Discussion
The present study demonstrated that the disruption of intestinal tight junction and adhesion junction and increase in intestinal permeability induced by pro-inflammatory stimuli could be mitigated by milk fat gangliosides consisting primarily of GD3 (Figure 6). This observation is consistent with findings in preclinical research models where dietary ganglioside inhibited degradation of tight junction protein occludin during LPS-induced acute inflammation in rats (13). Furthermore, bovine milk derived ganglioside mixture used in these experiments is similar to the composition of gangliosides present in human colostrum (23), predominantly GD3 (80%) with smaller amounts (20%) of GM3, GM1, and GD1a.
Figure 6
Secretory PLA2 activity results in a reduction in barrier integrity in CaCo-2 cells (24). Clinical research has shown sPLA2 to be increased in serum and colonic mucosa of patients with CD and UC (21). The present study suggests that LPS upregulates the concentration of sPLA2 and that DSS promotes trafficking of sPLA2 to the basolateral membrane (Figure 6). However, ganglioside GD3 promoted trafficking of sPLA2 to the apical membrane (Figure 6). Secretory PLA2 enzymes catalyze hydrolysis of the sn-2 position of membrane glycerophospholipids, leading to production of free fatty acids, mainly polyunsaturated fatty acids, and lysophospholipids. This reaction is of particular importance and depends on the fatty acid present in the sn-2 position. A long chain omega-3 fatty acid liberated at this position may be converted to pro-resolving mediators, but arachidonic acid may be converted to prostacyclin and bioactive eicosanoids including prostaglandins and leukotrienes. Dietary ganglioside downregulates production of pro-inflammatory mediators PGE2 and LTB4 in rats (25). Further research is needed to clarify how ganglioside regulates trafficking and secretion of sPLA2 at the apical and basolateral membranes and how the production of pro-inflammatory or pro-resolving lipid-derived mediators are affected.
Although enterocytes are targets of pathologic inflammation, enterocytes are also actively involved in immune tolerance (26) and generating an immune response at the mucosal level (27). Elevated levels of pro-inflammatory cytokines are observed in patients with IBD (28). HBD-2 and HBD-3 represent a link between innate and adaptive immune responses and are induced in intestinal dysbiosis (29) and during inflammation of CD and UC (30, 31). In the present study, ganglioside GD3 prevented the increase in IL-23 and secretion of HBD-2 induced by pro-inflammatory stimuli (Figure 6). Probiotic strains of bacteria can induce HBD-2 expression to function as a critical mediator of T-regulatory cell induction (32) and immune tolerance (33, 34). Taken together these data suggest that compromised immune tolerance in IBD caused by NOD2 and ATG16L1 variants (35) may be modulated by ganglioside to resolve mucosal inflammation independent of the presence of risk alleles.
Genetic polymorphisms of the IL-23 receptor (IL-23R) are frequently observed in IBD patients, signifying the importance of IL-23 and IL-23R signaling in IBD pathogenesis (36). Assembly of NF-κB facilitates IL-23 production (37) and the coordinated recruitment of Th17 cells (38). NF-κB has been identified as one of the key regulators in this immunological setting and central to the function of monocytes that exacerbate pro-inflammatory signaling. Macrophages and epithelial cells isolated from inflamed gut specimens from IBD patients showed augmented levels of NF-κB p65 (39). NF-κB subunits are kept inactive in the cytoplasm by an endogenous inhibitor protein of the IkB family (40). Under stimulation by IL-1 or LPS, IkB is phosphorylated, selectively ubiquitinated and rapidly degraded allowing NF-κB to translocate into the nucleus and induces target genes that have NF-κB binding domains (40). In IBD patients, increased NF-κB expression in mucosal macrophages is accompanied by increased capacity of these cells to produce and secrete TNF-α, IL-1, and IL-6 (39). In the present study, exposure of CaCo-2 cells to ganglioside GD3 mitigated the LPS-induced activation of NF-κB by attenuating production of the P65 and P52 subunits (Figure 6).
The lack of use of an anti-inflammatory control may be considered a limitation in this study. Whether the anti-inflammatory mode of action of gangliosides is similar to that of anti-inflammatory pharmaceuticals is unknow. In addition, only a single dose of ganglioside was used in the in vitro experiments. This was based on effective concentrations previously published (9) in addition to choosing a dose below the critical micellar concentration of gangliosides (41).
In summary, this study demonstrates that exposure of CaCo-2 cells to inflammatory stimuli produced some of the inflammatory responses characteristic of IBD. Exposure to ganglioside GD3 mitigated production of pro-inflammatory cytokines HBD-2 and IL-23 and this effect may be mediated by lowering NF-κB activation (Figure 6). Ganglioside GD3 mitigates the disruption of tight junctions induced by pro-inflammatory stimuli. Ganglioside protects intracellular phospholipid integrity by mitigating sPLA2 production and inhibiting sPLA2 trafficking to the basolateral membrane of enterocytes. Ganglioside may have potential therapeutic application either by inducing or maintaining remission in IBD as this research study has demonstrated downregulation of pro-inflammatory signaling in vitro.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.
Author contributions
JM (data curation: equal, resources: supporting, visualization: equal, writing—review and editing: equal). QL (conceptualization: supporting, formal analysis: lead, investigation: lead, methodology: lead, visualization: equal, writing—original draft: lead). JS (data curation: supporting, visualization: equal). AT (supervision: supporting). VM (supervision: supporting). MC (conceptualization: lead, funding acquisition: lead, resources: lead, supervision: lead, writing—review and editing: equal). All authors contributed to the article and approved the submitted version.
Funding
Funding was provided primarily by the Canadian Institutes of Health Research, award number 111077. Additional funding from Chapman University was provided for publishing fees.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
FretlandDJDjuricSWGaginellaTS. Eicosanoids and inflammatory bowel disease: regulation and prospects for therapy. Prostaglandins Leukot Essent Fatty Acids. (1990) 41:215–33. 10.1016/0952-3278(90)90135-8
2.
MiklavcicJJSchnablKLMazurakVCThomsonABClandininMT. Dietary Ganglioside reduces proinflammatory signaling in the intestine. J Nutr Metab. (2012) 2012:280–6. 10.1155/2012/280286
3.
LoCHLochheadPKhalilHSongMTabungFKBurkeKEet al. Dietary inflammatory potential and risk of Crohn's disease and Ulcerative Colitis. Gastroenterology. (2020) 159:873–3. 10.1053/j.gastro.2020.05.011
4.
YuRKNakataniYYanagisawaM. The role of glycosphingolipid metabolism in the developing brain. J Lipid Res. (2009) 50:S440–5. 10.1194/jlr.R800028-JLR200
5.
MiklavcicJJShoemakerGKSchnablKLLarsenBMThomsonABMazurakVCet al. Ganglioside intake increases plasma ganglioside content in human participants. J Parenter Enteral Nutr. (2017) 41:657–66. 10.1177/0148607115620093
6.
MiklavcicJJHartTDLeesGMShoemakerGKSchnablKLLarsenBMet al. Increased catabolism and decreased unsaturation of ganglioside in patients with inflammatory bowel disease. World J Gastroenterol. (2015) 21:10080–90. 10.3748/wjg.v21.i35.10080
7.
SchnablKLLarsenBVan AerdeJELeesGEvansMBelosevicMet al. Gangliosides protect bowel in an infant model of necrotizing enterocolitis by suppressing pro-inflammatory signals. J Pediatr Gastroenterol Nutr. (2009) 49:382–92. 10.1097/MPG.0b013e3181b6456d
8.
ParkEJSuhMThomsonBThomsonABRamanujamKSClandininMT. Dietary ganglioside decreases cholesterol content, caveolin expression and inflammatory mediators in rat intestinal microdomains. Glycobiology. (2005) 15:935–42. 10.1093/glycob/cwi078
9.
Rivas-SernaIMMazurakVCKeelanMClandininMT. Modification of ganglioside content of human gastric epithelial cell membrane decreases Helicobacter pylori adhesion. J Pediatr Gastroenterol Nutr. (2017) 65:456–61. 10.1097/MPG.0000000000001612
10.
DeWittRCKudskKA. The gut's role in metabolism, mucosal barrier function, and gut immunology. Infect Dis Clin North Am. (1999) 13:465–81. 10.1016/S0891-5520(05)70086-6
11.
KongJZhangZMuschMW. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol. (2008) 294:G208–16. 10.1152/ajpgi.00398.2007
12.
RawatMNighotMAl-SadiRGuptaYViszwapriyaDYochumGet al. IL1B increases intestinal tight junction permeability by up-regulation of MIR200C-3p, Which Degrades Occludin mRNA. Gastroenterology. (2020) 159:1375–89. 10.1053/j.gastro.2020.06.038
13.
ParkEJThomsonABClandininMT. Protection of intestinal occludin tight junction protein by dietary gangliosides in lipopolysaccharide induced acute inflammation. J Pediatr Gastroenterol Nutr. (2010) 50:321–28. 10.1097/MPG.0b013e3181ae2ba0
14.
DennisEA. The growing phospholipase A2 superfamily of signal transduction enzymes. Trends Biochem Sci. (1997) 22:1–2. 10.1016/S0968-0004(96)20031-3
15.
OppenheimJJBiragynAKwakLWYangD. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann Rheum Dis. (2003) 62:ii17–21. 10.1136/ard.62.suppl_2.ii17
16.
BarnesPJKarinM. Nuclear factor-κB—a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. (1997) 336:1066–71. 10.1056/NEJM199704103361506
17.
OppmannBLesleyRBlomBTimansJCXuYHunteBet al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. (2000) 13:715–25. 10.1016/S1074-7613(00)00070-4
18.
McGovernDPowrieF. The IL23 axis plays a key role in the pathogenesis of IBD. Gut. (2007) 56:1333–6. 10.1136/gut.2006.115402
19.
YzetCDioufMLe MouelJPBrazierFTurpinJLoreauJet al. Complete endoscopic healing associated with better outcomes than partial endoscopic healing in patients with Crohn's disease. Clin Gastroenterol Hepatol. (2020) 18:2256–61. 10.1016/j.cgh.2019.11.025
20.
LiQThomsonABClandininMT. Cholesterol ester and free fatty acids are modulated by Policosanol in CaCo-2 intestinal cells. J Am Coll Nutr. (2011) 30:201–9. 10.1080/07315724.2011.10719961
21.
MinamiTTojoHShinomuraYMatsuzawaYOkamotoM. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis. Gut. (1994) 35:1593–8. 10.1136/gut.35.11.1593
22.
Huynh-DelermeCHuetHNoelLFrigieriAKolf-ClauwM. Increased functional expression of P-glycoprotein in Caco-2 TC7 cells exposed long-term to cadmium. Toxicol In Vitro. (2005) 19:439–47. 10.1016/j.tiv.2004.08.003
23.
MaLMacGibbonAKHJan MohamedHJBLoySRowanAMcJarrowPet al. Determination of ganglioside concentrations in breast milk and serum from Malaysian mothers using a high performance liquid chromatography-mass spectrometry-multiple reaction monitoring method. Int Dairy J. (2015) 49:62–71. 10.1016/j.idairyj.2015.05.006
24.
SawaiTUsuiNDwaihyJDrongowskiRAAbeACoranAGet al. The effect of phospholipase A2 on bacterial translocation in a cell culture model. Pediatr Surg Int. (2000) 16:262–6. 10.1007/s003830050741
25.
ParkEJSuhMThomsonBMaDWRamanujamKThomsonABet al. Dietary ganglioside inhibits acute inflammatory signals in intestinal mucosa and blood induced by systemic inflammation of Escherichia coli lipopolysaccharide. Shock. (2007) 28:112–7. 10.1097/SHK.0b013e3180310fec
26.
CohenLJChoJHGeversDChuH. Genetic factors and the intestinal microbiome guide development of microbe-based therapies for inflammatory bowel diseases. Gastroenterology. (2019) 156:2174–89. 10.1053/j.gastro.2019.03.017
27.
FiocchiC. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. (1998) 115:182–205. 10.1016/S0016-5085(98)70381-6
28.
TazukeYDrongowskiRATeitelbaumDHCoranAG. Interleukin-6 changes tight junction permeability and intracellular phospholipid content in a human enterocyte cell culture model. Pediatr Surg Int. (2003) 19:321–5. 10.1007/s00383-003-1003-8
29.
MeadeKGO'FarrellyC. beta-Defensins: farming the microbiome for homeostasis and health. Front Immunol. (2018) 9:3072. 10.3389/fimmu.2018.03072
30.
WehkampJHarderJWeichenthalMMuellerOHerrlingerKRFellermannKet al. Inducible and constitutive β- defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. (2003) 9:215–23. 10.1097/00054725-200307000-00001
31.
KiehneKBrunkeGWegnerFBanasiewiczTFolschURHerzigKH. Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. World J Gastroenterol. (2006) 12:1056–62. 10.3748/wjg.v12.i7.1056
32.
DavidR. Regulatory T cells: a helping hand from Bacteroides fragilis. Nat Rev Immunol. (2010) 10:539. 10.1038/nri2827
33.
WehkampJHarderJWehkampKWehkamp-von MeissnerBSchleeMEndersCet al. NF-κBand AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun. (2004) 72:5750–8. 10.1128/IAI.72.10.5750-5758.2004
34.
SchleeMHarderJKotenBStangeEFWehkampJFellermannK. Probiotic lactobacilli and VSL# 3 induce enterocyte β- defensin 2. Clin Exp Immunol. (2008) 151:528–35. 10.1111/j.1365-2249.2007.03587.x
35.
ChuHKhosraviAKusumawardhaniIKwonAHKVasconcelosACCunhaLDet al. Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel disease. Science. (2016) 352:1116–20. 10.1126/science.aad9948
36.
KimDJKimKSSongMYSeoSHKimSJYangBGet al. Delivery of IL-12p40 ameliorates DSS-induced colitis by suppressing IL17A expression and inflammation in the intestinal mucosa. Clin Immunol. (2012) 144:190–9. 10.1016/j.clim.2012.06.009
37.
ChoMLKangJWMoonYMNamHJJhunJYHeoSBet al. STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol. (2006) 176:5652–61. 10.4049/jimmunol.176.9.5652
38.
LiuZYadavPKXuXSuJChenCTangMet al. The increased expression of IL-23 in inflammatory bowel disease promotes intraepithelial and lamina propria lymphocyte inflammatory responses and cytotoxicity. J Leukoc Biol. (2011) 89:597–606. 10.1189/jlb.0810456
39.
NeurathMFPetterssonSMeyer Zum BüschenfeldeKHStroberW. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF–κB abrogates established experimental colitis in mice. Nat Med. (1996) 2:998–1004. 10.1038/nm0996-998
40.
LiboniKCLiNScumpiaPONeuJ. Glutamine modulates LPS-induced IL-8 production through IkappaB/NF-kappaB in human fetal and adult intestinal epithelium. J Nutr. (2005) 135:245–51. 10.1093/jn/135.2.245
41.
FormisanoSJohnsonMLLeeGAlojSMEdelhochH. Critical micelle concentrations of gangliosides. Biochemistry. (1979) 18:1119–24. 10.1021/bi00573a028
Summary
Keywords
crohn, nutrition, ulcerative colitis, sphingolipid, immunology, inflammatory bowel disease, inflammation, intestinal permeability
Citation
Miklavcic JJ, Li Q, Skolnick J, Thomson ABR, Mazurak VC and Clandinin MT (2021) Ganglioside Alters Phospholipase Trafficking, Inhibits NF-κB Assembly, and Protects Tight Junction Integrity. Front. Nutr. 8:705172. doi: 10.3389/fnut.2021.705172
Received
04 May 2021
Accepted
04 June 2021
Published
05 July 2021
Volume
8 - 2021
Edited by
Ronan Lordan, University of Pennsylvania, United States
Reviewed by
Amruta Naik, Children's Hospital of Philadelphia, United States; Bradley Bolling, University of Wisconsin-Madison, United States
Updates
Copyright
© 2021 Miklavcic, Li, Skolnick, Thomson, Mazurak and Clandinin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: John J. Miklavcic miklavcic@chapman.edu
This article was submitted to Nutrition and Metabolism, a section of the journal Frontiers in Nutrition
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.